Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating autogene cevumeran added to nivolumab versus nivolumab alone in high-risk muscle-invasive urothelial carcinoma; the study is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Urothelial Carcinoma

Drugs mentioned

• Autogene Cevumeran (autogene cevumeran)
• nivolumab (nivolumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Muscle-invasive Urothelial Carcinoma | Phase 2 | Status: RECRUITING